Remifentanil Injection Shortage

• • Ultiva lyophilized powder for injection, Mylan Institutional (Viatris), 1 mg, vial, 10 count, NDC 72078-0034-01
  • Remifentanil lyophilized powder for injection, Fresenius Kabi, 1 mg, vial, 10 count, NDC 63323-0723-03
  • Remifentanil lyophilized powder for injection, Hikma, 1 mg, vial, 10 count, NDC 00143-9391-10
  • Remifentanil lyophilized powder for injection, Hikma, 2 mg, vial, 10 count, NDC 00143-9392-10

• • Fresenius Kabi has remifentanil injection available.
  • Hikma did not provide a reason for the shortage.
  • Viatris has remifentanil on shortage due to manufacturing delays.

• • Ultiva lyophilized powder for injection, Mylan Institutional (Viatris), 2 mg, vial, 10 count, NDC 72078-0035-02
  • Ultiva lyophilized powder for injection, Mylan Institutional (Viatris), 5 mg, vial, 10 count, NDC 67457-0198-10
  • Remifentanil lyophilized powder for injection, Fresenius Kabi, 2 mg, vial, 10 count, NDC 63323-0724-05
  • Remifentanil lyophilized powder for injection, Fresenius Kabi, 5 mg, vial, 10 count, NDC 63323-0725-10
  • Remifentanil lyophilized powder for injection, Hikma, 5 mg, vial, 10 count, NDC 00143-9393-10

Estimated Resupply Dates

• • Fresenius Kabi has remifentanil 1 mg vials on back order and the company estimates a release date of early-June 2024.
  • Hikma has remifentanil 1 mg vials on back order and the company estimates a release date of mid-June 2024. The 2 mg vials are on back order and the company cannot estimate a release date.
  • Viatris has Ultiva 1 mg vials on back order and the company estimates a release date of early-July 2024.